Interpace Biosciences

$4.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-3.82%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell IDXG and other stocks, options, and ETFs commission-free!

About IDXG

Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ. The listed name for IDXG is Interpace Biosciences, Inc. Common Stock.

CEO
Thomas W. Burnell
Employees
178
Headquarters
Parsippany, New Jersey
Founded
1986
Market Cap
16.97M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
129.56K
High Today
$4.21
Low Today
$4.01
Open Price
$4.02
Volume
75.24K
52 Week High
$11.00
52 Week Low
$2.57

Collections

IDXG Earnings

-$2.31
-$1.54
-$0.77
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
— per share
Actual
Expected Jan 26
Replay Earnings Call

You May Also Like

LNFA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure